Skip to main content
Premium Trial:

Request an Annual Quote

Monsanto Licenses CRISPR/Cpf1 From Broad Institute

NEW YORK (GenomeWeb) – Agricultural giant Monsanto has licensed CRISPR/Cpf1 genome editing technology from the Broad Institute.

Under the terms of the agreement, Monsanto gains worldwide, non-exclusive rights to agricultural applications of the CRISPR/Cpf1 system.

Financial and other terms of the agreement were not disclosed.

"The CRISPR/Cpf1 system is a powerful new discovery within the field of genome editing, and we're excited to license the system and add it to our growing portfolio of genome-editing tools," Monsanto biotechnology lead Tom Adams said in a statement.

Developed by Broad researcher Feng Zhang, also of the Massachusetts Institute of Technology, Cpf1 is an alternative — perhaps even complementary — CRISPR-based genome editing system. Compared to Cas9, Cpf1 features a smaller nuclease, different cleavage characteristics, shorter guide RNAs, and can recognize a different set of genomic targets.

In a statement, Monsanto said it is exploring genome editing in a phased approach across single-gene knock-outs, single-gene edits, and multiple-gene edits. It has also secured licenses to other genome-editing technologies, including a separate license from the Broad for use of the CRISPR/Cas9 system in ag-bio applications.

While ownership of CRISPR/Cas9 intellectual property is under dispute in the US, ownership of Cpf1 patents is not. It's the second license for genome editing applications of Cpf1. Last month, Editas Medicine licensed it from the Broad for use in human therapeutics.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.